Quantcast

Latest GlaxoSmithKline Stories

2014-10-16 08:30:25

EDISON, N.J., Oct. 16, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading contract research organization (CRO), to conduct a Phase 2b clinical trial of ContraVir's lead clinical asset, FV-100, in shingles patients. The planned Phase 2b study is...

2014-10-15 12:31:48

The COPD Market Will Fracture with the Continuing Entry of LABA/LAMAs and Other Later-to-Market Bronchodilators, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 15, 2014 /PRNewswire/ -- Decision Resources Group finds that the emergence of the long-acting beta(2) agonist (LABA)/long-acting muscarinic antagonist (LAMA) drug class will help drive total sales across the chronic obstructive pulmonary disease (COPD) market in the United States, France, Germany, Italy,...

2014-10-15 08:29:07

Proceeds to Fund Phase 2b Study of FV-100 Fast-Acting Oral Antiviral EDISON, N.J., Oct. 15, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has closed a private placement of shares of Series A Convertible Preferred Stock to a non-U.S. investor with gross proceeds of $9.0 million. The Preferred Stock is convertible at any time into...

2014-10-10 12:24:40

RALEIGH, N.C., Oct. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance. Mr. Prue brings more than 30 years of pharmaceutical industry experience in regulatory affairs and quality assurance to BDSI. He has held positions of increasing responsibility at The Upjohn Company, Glaxo Inc., GlaxoWellcome and Purdue Pharma LP. Recently...

2014-10-09 08:27:08

CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "ISIS-TTR(Rx) is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest...

2014-10-09 08:24:34

NEW YORK, Oct. 9, 2014 /PRNewswire/ -- A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for...

2014-10-08 12:26:37

Emerging Anticytokines, Are Expected to Drive the Market Growth and Open a New Era of Personalized Medicine in Asthma, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for asthma will remain stable, increasing slightly from $15.1 billion in 2013 to $16.1 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. As the current market leaders, which...

2014-10-02 12:31:33

Half of Surveyed Nephrologists Were Aware that the FDA had Approved American Regent's IV Iron Injectafer, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 2, 2014 /PRNewswire/ -- Decision Resources Group finds that approximately two-thirds of nephrologists do not differentiate among the oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors (Akebia's AKB-6548, FibroGen/AstraZeneca/Astellas's roxadustat, and GlaxoSmithKline's GSK-1278863A) based on the...

2014-09-29 08:31:20

DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Hepatitis B Vaccines Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the...

2014-09-29 08:30:22

DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related